


# THE THERALASE JOURNEY

**In a tough economy, WE excelled.** Sales reached an all-time record in the fourth quarter. We secured a partnership with a large Canadian Distributor and launched our Rehabilitation Centre. New break-throughs in scientific research came to fruition including the publication of a scientific study attesting to the superiority of Theralase's 905nm superpulsed technology over the competition. We made significant advancements with our TLC-3000 patented cancer destruction technology and completed a prototype for the TLC-2000, the next generation of therapeutic medical laser technology. New leaders emerged among staff and great successes were achieved. We are growing and fast!



1995

## Start of Theralase

Theralase Inc. is founded in July 1995 as a private Canadian Corporation with a mandate to build the finest therapeutic medical lasers in the world. Living true to this mandate, Theralase leads the industry with cutting-edge technology, world class customer service and exceptional value.

2002

## TLC-2000 BioFeedback

U.S. patent #6,413,276 issued in July 2002 for Theralase's advanced biofeedback technology. The TLC-2000 is able, for the first time in the world, to deliver a set dose of energy to a precise tissue depth.

2003

## Theralase Goes Public

In November 2003, Theralase is acquired by Interstar Group Inc. a public entity, and renamed as Theralase Technologies Inc. In September 2004, under this new operating structure, Theralase is able to further improve its current laser technology in a shorter period and aggressively pursue new technologies.

2004

## Overseas BioFeedback Patent

Theralase receives European patent #1075854 for its biofeedback technology.

## Health Canada Approval

Health Canada approves the Theralase TLC-1000 laser as a safe and effective treatment methodology under Health Canada Device Licence #65816.

2005

## 510k FDA Clearance (k050394)

Theralase receives FDA clearance after favourable review of its blinded randomized control study where 92.4% of patients treated reported a significant reduction in chronic knee pain.

## TLC-3000 Cancer Destroyer

U.S. patent #6,962,910 issues for the Theralase licenced photodynamic compounds.

2006

## Distinguished Additions to Scientific Advisory Board

Theralase appoints Dr. James Andrews to chair Theralase's medical and scientific advisory board with Dr. Jeff Dugas, Dr. Lyle Cain, Lanier Johnson, and Kevin Wilk elected as distinguished board members.

2007

## Industry Leaders Combine Forces

UHN, Theralase and OCE enters into a joint agreement to develop Theralase's patented photodynamic compound technology.

## Moved To Larger Facility

Theralase upgrades to a larger corporate facility to expand the rehabilitation clinic and the laser research and development center.

2008

## Partnering with Big Pharma

On April 18, 2008, Theralase is commissioned by a European pharmaceutical company to manufacture PDT light based systems for bacterial and viral inhibition.

## Launch of Theralase Rehabilitation Centre

Theralase launches Rehabilitation Centre for patient treatments and clinical studies.

2009

## Canada Wide Distribution

Theralase forms partnership with Royal Cross, a well-established and respected distribution company for Canada's health care industry.

2010

## Launch TLC-2000 Biofeedback

Theralase plans to launch its long-awaited TLC-2000 biofeedback laser. The technology can precisely target tissue with an exact dose of energy.

2013

## A Cure For Cancer

Theralase plans to launch the long awaited TLC-3000 laser, activated photodynamic compound (PDC) technology, for human cancer applications. This may be a paradigm shift in oncology if proven successful.

History

Future